|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 701 PENNSYLVANIA AVENUE, NW, #725 |
Address2 | |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 9204-12
|
||||||||
|
6. House ID# 335890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: James Elkin, Vice President and Head, US Public Affairs |
Date | 10/19/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 452 - Medicare Decisions Accountability Act of 2011
S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011
Gene Therapy
Personalized Medicine
H.R.2245 Preserving Access to Life-Saving Medications Act of 2011
S.296 Preserving Access to Life-Saving Medications Act
S.1206 Medicare Drug Savings Act of 2011
H.R.2190 Medicare Drug Savings Act of 2011
Section 9008 of Patient Protection and Affordable Care Act
Prescription Drug User Fee Act (PDUFA)
H.R.4872 Health Care and Education Reconciliation Act of 2010
S 75 - Generics First Act 2009
S 301 - Physician Payments Sunshine Act of 2009
H.R.759 Food and Drug Administration Globalization Act of 2009
HR 276 - Proper Disposal of Unused Pharmaceuticals
S1213 Patient-Centered Outcomes Research Act of 2009
HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program.
HR 1259 Dextromethorphan Distribution Act of 2009
S 1383 Dextromethorphan Abuse Reduction Act of 2009
S 256 Combat Methamphetamine Enhancement Act of 2009
HR 2923 Combat Methamphetamine Enhancement Act of 2009
S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes
S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
21st Century Cancer Bill
Public Health Service Act
Dextromethorphan - Age Restrictions - Controlling bulk shipments
Pseudoephedrine - Promote e-tracking; oppose Rx legislation
FSA/HSA - Support reinstating coverage of OTC products
Enhance supply and shipping parameters for beta-Propiolactone
Support incentives for development of new, innovative antibiotics (former GAIN Act)
MDUFA
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Shawn |
O'Neail |
|
|
|
David |
Drake |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
|
Katherine |
Solon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Free Trade Agreements:
- Intellectual Property Provisions in Panama, Colombia, Korea
Access to Medicines
Global Health Issues/Global Pandemic Influenza Planning
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), U.S. Agency for International Development (USAID), State - Dept of (DOS), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR 1458 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
S565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Pandemic Influenza Funding
FDA Appropriations funding for Generic Drugs
Certified Importer Program (CIP)
R 7110 Job Creation and Unemployment Relief Act of 2008
HR 1 American Recovery and Reinvetment Act
FY 2011 - DOD Appropriations Bill
2011 Continuing Resolutions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
|
Shawn |
O'Neail |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Access to Life Saving Medicines Act
Provide Medicare Part B Coverage for Vaccines Covered under Part D
Medicaid Coverage of Vaccines
HR2 Children's Health Insurance Program Reauthorization Act of 2009
S 275 Children's Health Insurance Program Reauthorization Act of 2009
HR 2800 Imported Food Safety Improvement Act of 2009
Medicare Prescription Drugs and Modernization Act
Immunosuppressant Legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
|
Shawn |
O'Neail |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Wage vs. Hour
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Shawn |
O'Neail |
|
|
|
David |
Drake |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
|
Katherine |
Solon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R.1249 - America Invents Act
S.23 - America Invents Act
Patent Settlement Legislation - 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Shawn |
O'Neail |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Orphan Drug Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Shawn |
O'Neail |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Brenda |
Luckritz |
|
|
|
Lisa |
Coen |
|
|
|
Sarah |
Haller |
|
|
|
Jennifer |
Young Maloney |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |